Table 1.
Characteristics of patients with COVID-19 according to endpoint
| With severe course | Without severe course | |
| N=465 | N=6990 | |
| Basic characteristics | ||
| Men, n (%) | 260 (55.9) | 3221 (46.1) |
| Age, mean±SD | 74.8±13.4 | 45.4±20.2 |
| History, n (%) | ||
| Hypertension | 258 (55.5) | 1266 (18.1%) |
| Atrial fibrillation | 75 (16.1) | 179 (2.6) |
| History of stroke | 55 (11.8) | 131 (1.9) |
| History of MI or PCI | 32 (6.9) | 106 (1.5) |
| Chronic heart failure | 90 (19.4) | 157 (2.2) |
| Chronic kidney disease | 99 (21.3) | 215 (3.1) |
| Diabetes mellitus | 127 (27.3) | 519 (7.4) |
| Chronic obstructive pulmonary disease | 102 (21.9) | 643 (9.2) |
| Acid-related disorders | 206 (44.3) | 999 (14.3) |
| Recent history of cancer (≤5 years) | 48 (10.3) | 169 (2.4) |
| Rheumatoid arthritis | 14 (3.0) | 75 (1.1) |
| Treatment, n (%) | ||
| ACE inhibitors | 182 (39.1) | 947 (13.5) |
| ARBs | 85 (18.3) | 543 (7.8) |
| Calcium channel blockers | 121 (26.0) | 584 (8.4) |
| Beta-blockers | 212 (45.6) | 884 (12.6) |
| Diuretics | 214 (46.0) | 814 (11.6) |
| Anticoagulants/antithrombotic agents | 143 (30.8) | 502 (7.2) |
| Statins | 169 (36.3) | 882 (12.6) |
ARBs, angiotensin II receptor blockers; MI, myocardial infarction; PCI, percutaneous coronary intervention.